KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

doi:10.4166/kjg.2021.112

KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

Original language	English
Pages (from-to)	105-116
Number of pages	12
Journal	The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume	78
Issue number	2
DOIs	https://doi.org/10.4166/kjg.2021.112
State	Published - 25 Aug 2021

Bibliographical note

Funding Information:
Dr. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; B2017/BMD-3740 AGES CM 2-CM), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda. Dr. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute. All other authors declare that they have no conflicts of interest.

Funding Information:
This work was supported in part by the grant PI16/00359 and PI18/1275 (Fondo de Investigaciones Sanitarias, FIS, and FEDER), by Madrid Regional Government (R&D activities in Biomedicine S2017/BMD-3740 (AGES-CM 2-CM)) and Structural Funds of the European Union, and by the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III.

Keywords

COVID-19
Disease management
Inflammatory bowel diseases
SARS-CoV-2

Access to Document

10.4166/kjg.2021.112

Cite this

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases (2021). KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 78(2), 105-116. https://doi.org/10.4166/kjg.2021.112

@article{4a6686b721f0441fa64d558995e3bb2e,

title = "KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.",

keywords = "COVID-19, Disease management, Inflammatory bowel diseases, SARS-CoV-2",

author = "{Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases} and Park, {Yong Eun} and Lee, {Yoo Jin} and Chang, {Ji Young} and Song, {Hyun Joo} and Kim, {Duk Hwan} and Yang, {Young Joo} and Kim, {Byung Chang} and Lee, {Jae Gon} and Yang, {Hee Chan} and Miyoung Choi and Kim, {Seong Eun} and Myung, {Seung Jae}",

note = "Funding Information: Dr. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigaci{\'o}n Sanitaria (FIS), Centro de Investigaci{\'o}n Biom{\'e}dica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; B2017/BMD-3740 AGES CM 2-CM), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda. Dr. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute. All other authors declare that they have no conflicts of interest. Funding Information: This work was supported in part by the grant PI16/00359 and PI18/1275 (Fondo de Investigaciones Sanitarias, FIS, and FEDER), by Madrid Regional Government (R&D activities in Biomedicine S2017/BMD-3740 (AGES-CM 2-CM)) and Structural Funds of the European Union, and by the Centro de Investigaci{\'o}n Biom{\'e}dica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III. ",

year = "2021",

month = aug,

day = "25",

doi = "10.4166/kjg.2021.112",

language = "English",

volume = "78",

pages = "105--116",

journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",

issn = "1598-9992",

publisher = "Korean Society of Gastroenterology",

number = "2",

}

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases 2021, 'KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement', The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, vol. 78, no. 2, pp. 105-116. https://doi.org/10.4166/kjg.2021.112

KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement. / Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases.
In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 78, No. 2, 25.08.2021, p. 105-116.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic

T2 - Expert Consensus Statement

AU - Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

AU - Park, Yong Eun

AU - Lee, Yoo Jin

AU - Chang, Ji Young

AU - Song, Hyun Joo

AU - Kim, Duk Hwan

AU - Yang, Young Joo

AU - Kim, Byung Chang

AU - Lee, Jae Gon

AU - Yang, Hee Chan

AU - Choi, Miyoung

AU - Kim, Seong Eun

AU - Myung, Seung Jae

N1 - Funding Information: Dr. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; B2017/BMD-3740 AGES CM 2-CM), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda. Dr. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute. All other authors declare that they have no conflicts of interest. Funding Information: This work was supported in part by the grant PI16/00359 and PI18/1275 (Fondo de Investigaciones Sanitarias, FIS, and FEDER), by Madrid Regional Government (R&D activities in Biomedicine S2017/BMD-3740 (AGES-CM 2-CM)) and Structural Funds of the European Union, and by the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III.

PY - 2021/8/25

Y1 - 2021/8/25

N2 - The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

AB - The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

KW - COVID-19

KW - Disease management

KW - Inflammatory bowel diseases

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85115140112&partnerID=8YFLogxK

U2 - 10.4166/kjg.2021.112

DO - 10.4166/kjg.2021.112

M3 - Review article

C2 - 34446633

AN - SCOPUS:85115140112

SN - 1598-9992

VL - 78

SP - 105

EP - 116

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

IS - 2

ER -

KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this